Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NETTER-3 first-line lutetium-177 dotatate in advanced GEP-NET
NL-OMON59329Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Nov 2025
- Modality
- Peptides, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, randomised trial of lutetium Lu 177 dotatate and octreotide in Gastroenteropancreatic Carcinoid Tumor (2 arms), sponsored by Novartis. Primary endpoint: Progression-free survival. Started Nov 2025; status: recruiting.
02
Drugs
lutetium Lu 177 dotatateoctreotide
03
Conditions
Gastroenteropancreatic Carcinoid Tumor
Beyond the preview
Go deeper on NL-OMON59329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59329.